Review Article
Antiepidermal Growth Factor Receptor Monoclonal Antibodies: Applications in Colorectal Cancer
Table 5
Trials using anti-EGFR mAbs plus bevacizumab in chemotherapy-resistant mCRC not selected by KRAS.
| | Trial (author) | Phase | Protocol | Number enrolled | Results | HR (95% CI) | value |
| | BOND-2 (Saltz et al.) [25] | II | Cetuximab + bevacizumab | 40 | TTP 4.9 mos. | | | | RR 20% | | | | OS 11.4 mos. | | | | Cetuximab + bevacizumab + irinotecan | 43 | TTP 7.3 mos. | | | | RR 20% | | | | OS 11.4 mos. | | |
| | BOND-2.5 (Segal et al.) [26] | II | Cetuximab + bevacizumab + irinotecan | 33 | | TTP 3.9 mos. | | | 9% PR
MS 10.6 mos. | | |
|
|
TTP: time to progression, RR: response rate, OS: overall survival, PR: partial response, and MS: median survival.
|
